178 related articles for article (PubMed ID: 20874640)
1. Cyclins against cancer: a novel family of tumor antigens?
Klein-González N; Kondo E; von Bergwelt-Baildon MS
Immunotherapy; 2010 Sep; 2(5):595-7. PubMed ID: 20874640
[No Abstract] [Full Text] [Related]
2. The cyclins: a family of widely expressed tumor antigens?
von Bergwelt-Baildon MS; Kondo E; Klein-González N; Wendtner CM
Expert Rev Vaccines; 2011 Mar; 10(3):389-95. PubMed ID: 21434806
[TBL] [Abstract][Full Text] [Related]
3. T-cell epitope peptide vaccines.
Elsawa SF; Rodeberg DA; Celis E
Expert Rev Vaccines; 2004 Oct; 3(5):563-75. PubMed ID: 15485336
[TBL] [Abstract][Full Text] [Related]
4. Considerations on clinical use of T cell immunotherapy for cancer.
Plautz GE; Cohen PA; Shu S
Arch Immunol Ther Exp (Warsz); 2003; 51(4):245-57. PubMed ID: 12956434
[TBL] [Abstract][Full Text] [Related]
5. Cellular and humoral immune responses of cancer patients to defined tumor antigens.
Jäger D; Jäger E; Bert F; Knuth A
Cancer Chemother Biol Response Modif; 2001; 19():385-93. PubMed ID: 11686025
[No Abstract] [Full Text] [Related]
6. [Perspectives for tumour immunology: antigen-specific immunotherapy of malignant diseases].
Jäger E; Jäger D; Knuth A
Dtsch Med Wochenschr; 2001 Sep; 126(37):1011-6. PubMed ID: 11555776
[No Abstract] [Full Text] [Related]
7. Effects of the tumor microenvironment on the efficacy of tumor immunotherapy.
Neeson P; Paterson Y
Immunol Invest; 2006; 35(3-4):359-94. PubMed ID: 16916758
[TBL] [Abstract][Full Text] [Related]
8. Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer.
Egloff AM; Vella LA; Finn OJ
Cancer Res; 2006 Jan; 66(1):6-9. PubMed ID: 16397206
[TBL] [Abstract][Full Text] [Related]
9. Cancer vaccines: pessimism in check.
Mocellin S; Mandruzzato S; Bronte V; Marincola FM
Nat Med; 2004 Dec; 10(12):1278-9; author reply 1279-80. PubMed ID: 15580242
[No Abstract] [Full Text] [Related]
10. Cancer immunotherapy: a treatment for the masses.
Blattman JN; Greenberg PD
Science; 2004 Jul; 305(5681):200-5. PubMed ID: 15247469
[TBL] [Abstract][Full Text] [Related]
11. Progress in human tumour immunology and immunotherapy.
Rosenberg SA
Nature; 2001 May; 411(6835):380-4. PubMed ID: 11357146
[TBL] [Abstract][Full Text] [Related]
12. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity.
Speiser DE; Romero P
Semin Immunol; 2010 Jun; 22(3):144-54. PubMed ID: 20413326
[TBL] [Abstract][Full Text] [Related]
13. [NY-ESO-1 and cancer immunotherapy].
Peng JR; Leng XS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Aug; 30(4):371-7. PubMed ID: 18795604
[TBL] [Abstract][Full Text] [Related]
14. Tumor vaccine: current trends in antigen specific immunotherapy.
Baral R
Indian J Exp Biol; 2005 May; 43(5):389-406. PubMed ID: 15900903
[TBL] [Abstract][Full Text] [Related]
15. Cancer immunotherapy with autologous and allogeneic vaccines: a practical overview.
Shinitzky M; Skornick Y
Prog Clin Biol Res; 1990; 348():95-125. PubMed ID: 2201036
[No Abstract] [Full Text] [Related]
16. Cancer vaccines: preclinical studies and novel strategies.
Palena C; Abrams SI; Schlom J; Hodge JW
Adv Cancer Res; 2006; 95():115-45. PubMed ID: 16860657
[TBL] [Abstract][Full Text] [Related]
17. Current developments of immunotherapy in the clinic.
Antonia S; Mulé JJ; Weber JS
Curr Opin Immunol; 2004 Apr; 16(2):130-6. PubMed ID: 15023403
[TBL] [Abstract][Full Text] [Related]
18. [Discovery of the splicing of peptides by the proteasome and study of preclinical models of anticancer immunotherapy].
Van den Eynde B
Bull Mem Acad R Med Belg; 2007; 162(5-6):352-6. PubMed ID: 18405005
[TBL] [Abstract][Full Text] [Related]
19. Current developments in cancer vaccines and cellular immunotherapy.
Ribas A; Butterfield LH; Glaspy JA; Economou JS
J Clin Oncol; 2003 Jun; 21(12):2415-32. PubMed ID: 12805342
[TBL] [Abstract][Full Text] [Related]
20. Adoptive cellular immunotherapy of cancer.
Winter H; Fox BA
Curr Opin Mol Ther; 1999 Feb; 1(1):89-97. PubMed ID: 11249690
[No Abstract] [Full Text] [Related]
[Next] [New Search]
